Clinical Trial Update: EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection Fraction [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the effects of empagliflozin on gut microbiota in patients with heart failure with preserved ejection fraction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Zhijun Sun | Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction | Phase 4 | Status: UNKNOWN